Strategic Financial Concepts LLC Invests $1.65 Million in Zoetis Inc. (NYSE:ZTS)

Strategic Financial Concepts LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, HoldingsChannel reports. The fund bought 10,102 shares of the company’s stock, valued at approximately $1,646,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Hedeker Wealth LLC boosted its holdings in shares of Zoetis by 1.4% during the 4th quarter. Hedeker Wealth LLC now owns 7,622 shares of the company’s stock worth $1,242,000 after purchasing an additional 108 shares during the last quarter. Telos Capital Management Inc. raised its position in shares of Zoetis by 4.3% during the 4th quarter. Telos Capital Management Inc. now owns 42,706 shares of the company’s stock valued at $6,958,000 after buying an additional 1,776 shares during the period. Oakworth Capital Inc. raised its position in shares of Zoetis by 1.5% during the 4th quarter. Oakworth Capital Inc. now owns 5,618 shares of the company’s stock valued at $915,000 after buying an additional 82 shares during the period. Financial Advocates Investment Management raised its position in shares of Zoetis by 81.8% during the 4th quarter. Financial Advocates Investment Management now owns 6,273 shares of the company’s stock valued at $1,022,000 after buying an additional 2,822 shares during the period. Finally, Legacy CG LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at approximately $4,400,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the topic of several analyst reports. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Piper Sandler cut their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $214.00.

Zoetis Stock Performance

NYSE:ZTS opened at $171.71 on Tuesday. The company has a fifty day simple moving average of $169.26 and a two-hundred day simple moving average of $179.21. The company has a market cap of $77.47 billion, a price-to-earnings ratio of 32.28, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.